{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:50:52Z","timestamp":1782334252885,"version":"3.54.5"},"reference-count":49,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>There are now six anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) approved for first-line ALK-positive non\u2013small cell lung cancer (NSCLC) therapy, improving survival and quality of life. However, real-world data on treatment outcomes, predictors of discontinuation, and sequencing strategies remain scarce, while direct comparisons between second- and third-generation TKIs are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This global longitudinal observational study evaluated patients with ALK-positive NSCLC, with data collected via online surveys from September 2022 to April 2025. Treatment patterns, outcomes, and factors associated with time to discontinuation (TTD) were assessed using descriptive statistics and univariable regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Overall, 1,111 patients from 71 countries were included (64% female; median age at diagnosis 53 years; 28% with a smoking history). Crizotinib was predominantly the first TKI administered, although prescribing patterns shifted over time (crizotinib before 2016, alectinib between 2017 and 2022, and lorlatinib thereafter). After the follow-up period (median of 20.7 months), 60% of patients remained on their initial TKI, with TTD varying significantly across agents. Factors associated with prolonged TTDs included radiotherapy, prior chemotherapy, delayed therapy initiation, and treatment in India (crizotinib) and retirement, prior chemotherapy, and treatment in the United Kingdom (alectinib). Gastroesophageal reflux disease, thyroid disease,\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      mutations, and\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      V3a\/b fusions were associated with a short TTD. Globally, alectinib to lorlatinib was the most common treatment sequence. Discontinuations because of toxicity were the highest with crizotinib and ceritinib and the lowest with lorlatinib and alectinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>This multinational registry-based analysis highlights evolving global treatment patterns, supports newer TKIs' effectiveness, and identifies clinical and molecular factors associated with treatment duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00574","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:59:11Z","timestamp":1782331151000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non\u2013Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population"],"prefix":"10.1200","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-3754","authenticated-orcid":true,"given":"Khalil","family":"Choucair","sequence":"first","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayat","family":"Bazzi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5041-076X","authenticated-orcid":true,"given":"Faten","family":"Abda","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Harb","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-7335","authenticated-orcid":true,"given":"Yasmin","family":"Snounu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vy","family":"Ong","sequence":"additional","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute, Biostatistics and Bioinformatics Core, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6048-1860","authenticated-orcid":true,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute, Biostatistics and Bioinformatics Core, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Barton","sequence":"additional","affiliation":[{"name":"ALK Positive Inc, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-8703","authenticated-orcid":true,"given":"Hirva","family":"Mamdani","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5240-3811","authenticated-orcid":true,"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[{"name":"Henry Ford Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-0550","authenticated-orcid":true,"given":"Morhaf","family":"Al Achkar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051578"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00973-7"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194765"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.4794"},{"key":"e_1_3_7_6_2","volume-title":"Crizotinib FDA Prescribing Information","author":"US Food and Drug Administration (FDA)","year":"2023","unstructured":"US Food and Drug Administration (FDA): Crizotinib FDA Prescribing Information, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202570s036lbl.pdf"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3523"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30123-X"},{"key":"e_1_3_7_9_2","volume-title":"Ceritinib FDA Prescribing Information","author":"US Food and Drug Administration (FDA)","year":"2021","unstructured":"US Food and Drug Administration (FDA): Ceritinib FDA Prescribing Information, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/205755s019lbl.pdf"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.478"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100527"},{"key":"e_1_3_7_12_2","volume-title":"Lorlatinib FDA Prescribing Information","author":"US Food and Drug Administration (FDA)","year":"2021","unstructured":"US Food and Drug Administration (FDA): Lorlatinib FDA Prescribing Information, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210868s004lbl.pdf"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00581"},{"key":"e_1_3_7_14_2","volume-title":"Alectinib FDA Prescribing Information","author":"US Food and Drug Administration (FDA)","year":"2024","unstructured":"US Food and Drug Administration (FDA): Alectinib FDA Prescribing Information, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208434s015lbl.pdf"},{"key":"e_1_3_7_15_2","volume-title":"Brigatinib FDA Prescribing Information","author":"US Food and Drug Administration (FDA)","year":"2022","unstructured":"US Food and Drug Administration (FDA): Brigatinib FDA Prescribing Information, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208772s013lbl.pdf"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8015"},{"key":"e_1_3_7_18_2","volume-title":"Cancer Registration: Principles and Methods","author":"Jensen OM","year":"1991","unstructured":"Jensen OM: Cancer Registration: Principles and Methods. Lyon, IARC, 1991"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235756"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072623"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.926890"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.1379"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.10.001"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S156170"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107919"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100157"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.03.014"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.03.005"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.04.019"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02744"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6052"},{"key":"e_1_3_7_35_2","first-page":"100881","article-title":"Meta-analysis exploring tyrosine kinase inhibitors-induced weight gain in oncogene-addicted non-small-cell lung cancer","volume":"6","author":"Scaglione IM","year":"2025","unstructured":"Scaglione IM, Avancini A, Eccher S, et al: Meta-analysis exploring tyrosine kinase inhibitors-induced weight gain in oncogene-addicted non-small-cell lung cancer. JTO Clin Res Rep 6:100881, 2025","journal-title":"JTO Clin Res Rep"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2016.1179821"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3308-7"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9957-3"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100880"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.11.007"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25422"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03151-2"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100443"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0179-8"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx380.032"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf005"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy333"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.05.61"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26886"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78152-1"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:59:27Z","timestamp":1782331167000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/GO-25-00574"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00574","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500574"}}